BACKGROUND & AIMS: Predictors of response to treatment with peginterferon plus ribavirin are well established. In these post-hoc analyses of the REALIZE study, we sought to identify predictors of response for telaprevir-based triple therapy. METHODS: Patients from the REALIZE study with baseline data for all predictors evaluated (including baseline disease characteristics and demographics, prior treatment response and baseline laboratory assessments) were included in the post-hoc analyses (n = 465). Univariate and multivariate analyses were used to evaluate factors predicting treatment outcomes. RESULTS: Sustained viral response (SVR) rates were 86% in prior relapsers, 63% in prior partial responders and 32% in prior null-responders. In the final multivariate analysis, baseline factors predicting SVR were prior response to treatment [Odds ratio (OR) = 2.80; 95% confidence interval (CI), 2.13-3.69], low-density lipoprotein (LDL) (≥2.6 mmol/L) (OR = 2.11; 95% CI, 1.52-2.93), HCV genotype (OR = 0.58; 95% CI, 0.36-0.93), and maximum alanine amino transferase and aspartate amino transferase (OR = 0.62; 95% CI, 0.40-0.97). CONCLUSIONS: Prior response to peginterferon plus ribavirin treatment and LDL levels are the main independent predictive markers of response with telaprevir-based triple therapy.

Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study / Berg, Thomas; Andreone, Pietro; Pol, Stanislas; Roberts, Stuart; Younossi, Zobair; Diago, Moises; Lawitz, Eric J.; Focaccia, Roberto; Foster, Graham R.; Horban, Andrzej; Lonjon-Domanec, Isabelle; Demasi, Ralph; Picchio, Gaston; Luo, Donghan; De Meyer, Sandra; Zeuzem, Stefan. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 35:2(2015), pp. 448-454. [10.1111/liv.12703]

Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study

Pietro Andreone;
2015

Abstract

BACKGROUND & AIMS: Predictors of response to treatment with peginterferon plus ribavirin are well established. In these post-hoc analyses of the REALIZE study, we sought to identify predictors of response for telaprevir-based triple therapy. METHODS: Patients from the REALIZE study with baseline data for all predictors evaluated (including baseline disease characteristics and demographics, prior treatment response and baseline laboratory assessments) were included in the post-hoc analyses (n = 465). Univariate and multivariate analyses were used to evaluate factors predicting treatment outcomes. RESULTS: Sustained viral response (SVR) rates were 86% in prior relapsers, 63% in prior partial responders and 32% in prior null-responders. In the final multivariate analysis, baseline factors predicting SVR were prior response to treatment [Odds ratio (OR) = 2.80; 95% confidence interval (CI), 2.13-3.69], low-density lipoprotein (LDL) (≥2.6 mmol/L) (OR = 2.11; 95% CI, 1.52-2.93), HCV genotype (OR = 0.58; 95% CI, 0.36-0.93), and maximum alanine amino transferase and aspartate amino transferase (OR = 0.62; 95% CI, 0.40-0.97). CONCLUSIONS: Prior response to peginterferon plus ribavirin treatment and LDL levels are the main independent predictive markers of response with telaprevir-based triple therapy.
2015
35
2
448
454
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study / Berg, Thomas; Andreone, Pietro; Pol, Stanislas; Roberts, Stuart; Younossi, Zobair; Diago, Moises; Lawitz, Eric J.; Focaccia, Roberto; Foster, Graham R.; Horban, Andrzej; Lonjon-Domanec, Isabelle; Demasi, Ralph; Picchio, Gaston; Luo, Donghan; De Meyer, Sandra; Zeuzem, Stefan. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 35:2(2015), pp. 448-454. [10.1111/liv.12703]
Berg, Thomas; Andreone, Pietro; Pol, Stanislas; Roberts, Stuart; Younossi, Zobair; Diago, Moises; Lawitz, Eric J.; Focaccia, Roberto; Foster, Graham R.; Horban, Andrzej; Lonjon-Domanec, Isabelle; Demasi, Ralph; Picchio, Gaston; Luo, Donghan; De Meyer, Sandra; Zeuzem, Stefan
File in questo prodotto:
File Dimensione Formato  
Liv_Int_2014.pdf

Accesso riservato

Dimensione 329.58 kB
Formato Adobe PDF
329.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237281
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 4
social impact